Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 4 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Liver Cancer Therapeutics Market to 2018 - Introduction | 9 | 1 |
| Liver Cancer Therapeutics Market to 2018 - Overview | 10 | 9 |
| Introduction | 10 | 1 |
| Benign Tumor | 10 | 1 |
| Hemangioma | 10 | 1 |
| Hepatic Adenoma | 10 | 1 |
| Focal Nodular Hyperplasia | 10 | 1 |
| Primary Liver Cancer | 10 | 1 |
| Hepatocellular Carcinoma | 10 | 1 |
| Intrahepatic Cholangiocarcinoma | 10 | 1 |
| Angiosarcomas and Hemangiosarcomas | 10 | 1 |
| Hepatoblastoma | 10 | 1 |
| Secondary Liver Cancer | 10 | 1 |
| Symptoms | 11 | 1 |
| Diagnosis | 11 | 1 |
| Laboratory Tests | 11 | 1 |
| Liver Function Tests | 11 | 1 |
| Alpha-fetoprotein Blood Test | 11 | 1 |
| Imaging Tests | 11 | 1 |
| Ultrasound | 11 | 1 |
| Computed Tomography Scan | 11 | 1 |
| Magnetic Resonance Imaging | 11 | 1 |
| Angiography | 12 | 1 |
| Bone Scan | 12 | 1 |
| Others | 12 | 1 |
| Biopsy | 12 | 1 |
| Laparoscopy | 12 | 1 |
| Treatment Options | 12 | 1 |
| Surgery | 13 | 1 |
| Resection | 13 | 1 |
| Liver Transplant | 13 | 1 |
| Non-surgical | 13 | 1 |
| Transarterial Chemoembolization | 13 | 1 |
| Intra-arterial Chemotherapy | 13 | 1 |
| Ablation Therapy | 13 | 1 |
| Radiation Therapy | 14 | 1 |
| Systemic Therapy | 14 | 1 |
| Chemotherapy | 14 | 1 |
| Targeted Therapy | 14 | 1 |
| General Treatment Algorithm | 15 | 1 |
| Treatment by Stage | 16 | 1 |
| Stages I and II (Localized) | 16 | 1 |
| Stage III and Stage IV (Regional and Distant) | 17 | 1 |
| New Technologies in Treatment | 18 | 1 |
| Radiation therapy | 18 | 1 |
| Targeted Therapy | 18 | 1 |
| Virus Therapy | 18 | 1 |
| Liver Cancer Therapeutics Market to 2018 - Market Characterization and Forecasts | 19 | 11 |
| Revenue | 19 | 3 |
| Annual Cost of Therapy | 22 | 1 |
| Marketed Products | 23 | 1 |
| Nexavar | 23 | 1 |
| Introduction | 23 | 1 |
| Mechanism of Action | 23 | 1 |
| Clinical Studies - Results from Sorafenib HCC Assessment Randomized Protocol (SHARP) Trial Study | 23 | 1 |
| Adverse Reactions | 24 | 1 |
| Approval History of Nexavar | 25 | 1 |
| Miripla | 25 | 1 |
| Introduction | 25 | 1 |
| Mechanism of Action | 25 | 1 |
| Clinical Studies | 25 | 1 |
| Safety | 26 | 1 |
| Approval History of Miripla | 26 | 1 |
| Treatment Usage Pattern | 27 | 1 |
| Prevalence Population | 28 | 1 |
| Diagnosed Population | 28 | 1 |
| Prescription Population | 28 | 1 |
| Drivers and Barriers of Liver Cancer Therapeutics Market | 28 | 1 |
| Drivers | 28 | 1 |
| High Incidence Rate | 28 | 1 |
| High Activity in Pipeline | 28 | 1 |
| High Unmet Need | 28 | 1 |
| Barriers | 29 | 1 |
| Poor Hepatocellular Carcinoma Prognosis | 29 | 1 |
| Affordability of High-cost Treatment | 29 | 1 |
| Lack of Medical Expertise for Early Diagnosis | 29 | 1 |
| Liver Cancer Therapeutics Market to 2018 - Geographical Landscape | 30 | 11 |
| US | 30 | 1 |
| Introduction | 30 | 1 |
| Revenue | 30 | 2 |
| Cost of Therapy | 32 | 1 |
| Treatment Usage Pattern | 33 | 1 |
| Top Five European Countries | 34 | 1 |
| Introduction | 34 | 1 |
| Revenue | 34 | 2 |
| Cost of Therapy | 36 | 1 |
| Treatment Usage Pattern | 37 | 1 |
| Japan | 38 | 1 |
| Introduction | 38 | 1 |
| Revenue | 38 | 1 |
| Cost of Therapy | 39 | 1 |
| Treatment Usage Pattern | 40 | 1 |
| Liver Cancer Therapeutics Market to 2018 - Pipeline Analysis | 41 | 10 |
| Introduction | 41 | 2 |
| R&D Product Pipeline by Stage of Development | 43 | 1 |
| Phase III | 43 | 1 |
| Phase II/III | 44 | 1 |
| Phase II | 44 | 1 |
| Phase I/II | 45 | 1 |
| Phase I | 46 | 1 |
| Pre-Clinical | 47 | 1 |
| Discovery | 47 | 1 |
| Profiles of Promising Molecules | 48 | 1 |
| PrevOnco | 48 | 1 |
| Product Description | 48 | 1 |
| Mechanism of Action | 48 | 1 |
| Clinical Study Details | 48 | 1 |
| Ramucirumab | 48 | 1 |
| Product Description | 48 | 1 |
| Mechanism of Action | 49 | 1 |
| Clinical Study Details | 49 | 1 |
| ThermoDox | 49 | 1 |
| Product Description | 49 | 1 |
| Mechanism of Action | 49 | 1 |
| Clinical Study Details | 49 | 1 |
| Afinitor | 50 | 1 |
| Product Description | 50 | 1 |
| Mechanism of Action | 50 | 1 |
| Clinical Study Details | 50 | 1 |
| Liver Cancer Therapeutics Market to 2018 - Competitive Landscape | 51 | 2 |
| Bayer | 51 | 1 |
| Dainippon Sumitomo Pharma | 52 | 1 |
| Liver Cancer Therapeutics Market to 2018 - Strategic Consolidations | 53 | 11 |
| Introduction | 53 | 1 |
| Deals by Geography | 54 | 1 |
| Deals by Year | 55 | 1 |
| Mergers and Acquisition Deals | 56 | 1 |
| Overview | 56 | 1 |
| Profiles of Major M&A Deals | 57 | 1 |
| DNAtrix Merges with VectorLogics | 57 | 1 |
| GlaxoSmithKline Completes Acquisition of Human Genome Sciences for $3.6 Billion | 57 | 1 |
| North Horizon Completes Acquisition of FasTrack Pharma in Reverse Acquisition | 57 | 1 |
| Pharmascience Acquires Aegera Therapeutics | 57 | 1 |
| Myotec Therapeutics Merges with Hybrid BioSystems | 58 | 1 |
| Licensing Agreements | 58 | 1 |
| Overview | 58 | 2 |
| Profiles of Major Licensing Agreements | 60 | 1 |
| Astellas Pharma Enters into Licensing Agreement with AVEO Pharma for Tivozanib | 60 | 1 |
| Alnylam Pharma Enters into Licensing Agreement with Ascletis Pharma to Develop ALN-VSP | 60 | 1 |
| GE Healthcare Enters into Licensing Agreement with Dyax for c-Met Imaging Peptides | 61 | 1 |
| 4SC Enters into Licensing Agreement with Yakult Honsha for Resminostat | 61 | 1 |
| Ono Pharma Enters into Licensing Agreement with OncoTherapy | 61 | 1 |
| Co-Development Agreements | 62 | 1 |
| Overview | 62 | 1 |
| Profiles of Major Co-Development Agreements | 63 | 1 |
| Beijing Genomics Institute Enters into Co-Development Agreement with Asia Cancer Research Group | 63 | 1 |
| Ludwig Institute Enters into Co-Development Agreement with Polaris for ADI-PEG 20 | 63 | 1 |
| Pfizer Enters into an Agreement with Samsung Medical Center | 63 | 1 |
| Indivumed Expands Collaboration with Georgetown University | 63 | 1 |
| Liver Cancer Therapeutics Market to 2018 - Appendix | 64 | 9 |
| Market Definitions | 64 | 1 |
| Abbreviations | 64 | 2 |
| Bibliography | 66 | 1 |
| Research Methodology | 67 | 2 |
| Coverage | 67 | 1 |
| Secondary Research | 68 | 1 |
| Primary Research | 68 | 1 |
| Therapeutic Landscape | 69 | 2 |
| Epidemiology-Based Forecasting | 69 | 1 |
| Market Size by Geography | 70 | 1 |
| Geographical Landscape | 71 | 1 |
| Pipeline Analysis | 71 | 1 |
| Competitive Landscape | 72 | 1 |
| Expert Panel Validation | 72 | 1 |
| Contact Us | 72 | 1 |
| Disclaimer | 72 | 1 |
